C WorldWide Group Holding A S Has $15.47 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

C WorldWide Group Holding A S lessened its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 18.9% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,809 shares of the company's stock after selling 20,000 shares during the period. C WorldWide Group Holding A S owned approximately 0.30% of Krystal Biotech worth $15,471,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in KRYS. Fifth Third Bancorp lifted its holdings in Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after purchasing an additional 105 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Krystal Biotech during the 4th quarter worth $95,000. Covestor Ltd lifted its holdings in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after buying an additional 642 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after acquiring an additional 432 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new position in shares of Krystal Biotech in the first quarter valued at about $223,000. Institutional investors own 86.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on KRYS shares. Citigroup reissued a "neutral" rating and issued a $176.00 price objective (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. HC Wainwright reiterated a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Tuesday, June 24th. Guggenheim reduced their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech has a consensus rating of "Buy" and a consensus price target of $213.75.

Krystal Biotech Price Performance

NASDAQ:KRYS traded down $2.66 during mid-day trading on Friday, reaching $147.49. The stock had a trading volume of 303,976 shares, compared to its average volume of 287,068. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $219.34. The stock has a market capitalization of $4.26 billion, a PE ratio of 35.45 and a beta of 0.67. The stock has a 50-day simple moving average of $136.27 and a two-hundred day simple moving average of $156.00.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The business had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Equities analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the business's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the transaction, the insider owned 1,508,056 shares of the company's stock, valued at approximately $226,208,400. The trade was a 0.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 49,800 shares of company stock valued at $7,487,943 over the last quarter. Company insiders own 13.70% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).